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In vivo emergence of a highly metastatic tumour cell line from a rat
rhabdomyosarcoma after treatment with an alkylating agent
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IRSC-CNRS, ER 278, Biologie des Metastases, B.P. No. 8, 94802 Villejuf, Cedex, France.
Summary Rats bearing a transplanted nickel-induced rhabdomyosarcoma (RMS 9-4/0), treated with
chlorozotocin (CZT), an alkylating agent, showed an amplified metastatic invasion of the lung (median of 165
lung tumour nodules, compared to 3 for untreated controls). A higher level of metastatic invasion (200
nodules) was reached spontaneously after the grafting of the S4T line, which was obtained by successive in
vivo passages of RMS 9-4/0 cells in CZT treated rats. S4T tumour cells also invaded the liver and a
considerable proportion of the lymph nodes. The NT4T line, obtained by successive in vivo passages in
untreated rats, showed a lesser degree of enhancement of metastatic capacity (57 nodules). Both derived lines
proved to be more aggressive than the parental, proliferated more rapidly, and were resistant to CZT toxicity.
Only the non-treated lineage became more resistant to NK lysis. The S4T line lost its myogenic differentiation
and was best described as a fibrohistiosarcoma, whereas NT4T did not. Chromosome analysis demonstrated a
reduced range of chromosome number per cell in both lines. We conclude that both S4T and NT4T tumours
became more metastatic than RMS 9-4/0 as the result of tumour progression through in vivo passages, and
that in addition S4T acquired a spontaneously higher metastatic potential, similar to that which occurred in
rats grafted with RMS 9-4/0 or NT4T tumours and treated by CZT. This suggests an inheritable mutation in
the S4T line.
A major problem of cancer therapy is the emergence of
tumour subpopulations resistant to the treatment. The
probability that a tumour will generate resistant variants
could be related to genetic instability (Goldie & Coldman,
1984; Stephens et al., 1986). According to Cifone and Fidler
(1981), genetic instability is also an important characteristic
of metastatic cell lines. Therapy would, therefore, possibly
select subpopulations that are potentially the most metastatic
in the tumour. On the other hand, previous studies suggested
that chemotherapy, since it uses potentially mutagenic
agents, could be responsible for tumour progression towards
a more malignant phenotype (Kerbel & Davies, 1982).
Repair mechanisms may allow mutated cells to survive, and
increase both tumour drug resistance and phenotypic
heterogeneity.
We have described the enhancing effect of a nitrosourea,
chlorozotocin 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-gluco-
pyranose (CZT), on the metastatic ability of RMS 9-4/0, a rat
rhabdomyosarcoma (Poupon et al., 1984). We hypothesized
that this action was due to the emergence of a subpopulation
of the RMS 9-4/0 tumour, that was both resistant to CZT
and highly metastatic. We failed to obtain a selection for
CZT resistance in the primary tumour because the treated
rats were rapidly killed by the growth of lung metastases. To
overcome this, the treated primary tumour cells were injected
into new recipients that were also treated and this cycle was
repeated until a fully resistant population was obtained. The
metastatic ability of these cells was then studied.
Materials and methods
Animals
Ten to 12 week old female Wistar AG (WAG) rats, bred at
the Institut de Recherches Scientifiques sur le Cancer and
maintained in pathogen-limited conditions, were used.
Tumours
RMS 9-4/0 is a rhabdomyosarcoma induced in our
laboratory by an i.m. injection of 20mg of colloidal nickel
(Prolabo, France) into the thigh of a WAG rat (Sweeney et
al., 1982). When it reached 20mm in diameter, the tumour
was removed and dissociated in a 0.25% trypsin solution.
The cells were plated and maintained as a continuous line in
Dulbecco's modified Eagle's medium (DMEM) (Grand
Island Biological Co., Grand Island, NY) supplemented with
10% heat-inactivated foetal calf serum (Flow Laboratories,
UK) and an antibiotic solution of streptomycin-penicillin
(10 jgml-1). Cells were detached by trypsinization from
subconfluent cultures. A suspension of I05 cells in 0.1 ml of
medium was injected s.c. into the flanks of syngeneic rats
midway between the inguinal and axillary areas.
A group of the tumour-bearing rats were not drug-treated
and gave rise to the NT(x)T tumour lineage, where (x)
designates the number of cycles performed. When rats were
moribund the tumour was excised, finely minced with a
scalpel, and then allowed to grow in the complete medium
described above. At confluence, cells were injected s.c. into
new animals. Part of the cells were frozen for further
analyses.
Other tumour-bearing rats were treated weekly with i.p.
injections (10mgkg-1) of chlorozotocin (diluted in PBS,
kept frozen at -200C, and thawed immediately before
injection). The tumour lineage thus established was named
S(x)T and was passed into new animals as described above.
In the NT(x)T group, some of the rats were also treated
with CZT, similarly to the S(x)T group, as a control of CZT
efficiency.
In the S(x)T group, some of the rats were not treated in
order to assess the evolution of spontaneous metastatic
ability in the S(x)T lineage (Figure 1).
In both groups, the animals were examined weekly after
tumour inoculation. Following the appearance of palpable
tumours, these were measured (the average of two diameters)
once weekly until death. Differences in tumour diameters
were analysed by Student's t test. Moribund animals were
killed and examined for metastatic invasion. Differences in
the number of lung colonies were analysed with Wilcoxon's
test. Metastases, especially in the lungs and the liver, were
confirmed by histological examination. In general, the least
necrotic tumour in each group was kept and put into
culture.
Chromosome analysis
For chromosome preparation, 106 cells were treated in vitro
with colchicine at a final concentration of 5 jgml-'
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Figure 1 Selection procedure of the S(x)T lineage. Syngeneic rats
received a s.c. graft of RMS 9-4/0 parental cells, and were
separated into two groups. Rats of one group (below) were given
5 weekly injections of 10mgkg-' CZT when the tumour
diameter reached 10mm. One tumour was established in culture
and was called SIT. The sequence of x identical cycles gave rise
to the S(x)T lineage, (x) designates the number of cycles
performed. The second group (above) was not treated with CZT
and gave rise to the NT(x)T lineage, according to the same
procedure. NT(x)T cell lines were assayed for their sensitivity to
CZT (uppermost line). S(x)T cell lines were assayed for their
spontaneous metastatic ability (lowermost line).
complete medium. Eighteen hours after colchicine treatment,
the cells were trypsinized and treated with a hypotonic
solution (2.8 g KCl/liter of distilled water) for 15min at
37°C. They were then rinsed and fixed in absolute methanol
and glacial acetic acid (3:1, v/v), smeared onto a cold wet
slide, gently flame dried and stained for 10min with 2%
Giemsa blue. The slides were examined with a Leitz
orthoplan microscope. For each cell line 100 smears were
scored.
Natural killer (NK) lysis assay
Tumour cells were harvested from subconfluent cultures by
trypsinization and incubated at 37°C for 2h with lOO1uCi
"Cr (New England Nuclear, W. Germany) in Dulbecco's
modified Eagle's medium (DMEM). After washing, the cells
were counted and viability assessed by trypan blue dye
exclusion, and the suspension was then adjusted to 105
viable cellsml-1. The spleen of a WAG rat was dissociated
and the number of viable cells was determined. Labelled
target cells and splenic effectors were suspended in DMEM
supplemented with 10% FCS; 4 dilutions of effector cells
were prepared to give effector: target ratios of 200, 100, 50
and 25:1 labelled target cell in a final volume of 0.2ml
performed in triplicate in a microtest culture plate.
After a 5h incubation at 37°C in a 5% Co2 atmosphere,
0.1 ml of supernatant was harvested from each well and the
radioactivity was monitored in an LKB gamma counter. The
percent lysis was calculated from the formula 100 x (E-S)/
(T-S) where E = cpm released in the wells containing effector
and target cells; S = cpm released in the wells containing
target cells and medium alone (spontaneous release); and
T = cpm released in the wells containing target cells and 1 N
hydrochloric acid solution (maximum lysis). Three
experiments were performed that gave similar results. Each
experiment gave identical relationships for a given cell line,
although there were differences in the actual values obtained.
Figure 5 shows the results of one experiment. Regression
analysis was performed and computed values used for the
discussion.
Results
In vivo behaviour of the tumour cell lines
9-4/0 parental cell line When injected into WAG rats, 9-4/0
tumour cells killed their hosts in about 86 days (Table I),
when the tumour's mean diameter (MD) reached -40mm
(37+1mm). The median number of lung metastases (LM)
was 3 (range 0-26) and only a few, mainly peripheral, lymph
nodes (LN) were invaded. CZT treatment had an evident
inhibitory effect on tumour growth rate, the MD of CZT-
treated rat tumours being 15+1 vs. 23 +2 mm for controls on
day 55, (P<0.01) (Figure 2), but the rat survival time was
shortened (56+2 days). This reduced life span was due to the
dramatic enhancement of the LM number (median of 165,
range 32-181, P<0.01). CZT treatment had no effect on LN
invasion.
NT(x)T lineage A progressive enhancement of the NT(x)T
lineage's metastatic abilities through in vivo passages was
observed, both in the lungs (for NT4T, the median LM was
Table I In vivo behaviour of tumour cell lines
Mean
survival
Cell time
line (days)
Primary Inguinal
tumoura lymph nodes?
Axillary Mesenteric Liver Lumbaraortic Mediastinal Lung
lymph nodesa lymph nodesa metastasis lymph nodes? lymph nodes' metastasis
RMS 9-4/0 86 37.1 5.3
+4.6 +1.5 +2.7
(6/10)
RMS 9-4/0 56 15.5 (5/10)
32
+1.2
(P<0.01)
32
+2.1
32
+0.8
(P>0.05)
+1.5
43.1 15.4c
+0.7 +2.4
(10/10)
28.2 15.OC
+3.1 +2.0
(10/10)
41.2 20.4C
+1.0 +1.2
(9/9)
37.3 20.0c
+1.5 +1.0
(10/10)
8.2
+2.0
(6/10)
8.2
+2.9
(8/10)
30.8
+2.0
(10/10)
21.9c
+1.8
(10/10)
37.2c
+0.9
(9/9)
28.1c
+ 1.8
(10/10)
3
(0-26)
165
(32-181)
1/10 3.8
+1.1
(6/10)
2/10
3/9 4/9
3/10 3/10
13.9
+2.1
(9/9)
14.6
+1.3
(10/10)
3+ 57
(6/10) (12-93)
- 188
(44-TMTC)
2+ >200
(8/9) (146-TMTC)
4+ 191
(9/10) (23-TMTC)
+CZT +2.0
(P<0.01)
NT4T 44
+1.5
NT4T
+CZT
S4T
S4T
+CZT
Ten tumour-bearing rats from groups that have been treated identically were examined at autopsy for their metastatic invasion. Autopsy
was performed when rats were moribund. One S4T tumour-bearing rat died several days before the remainder of the group, and was not
included in the analysis. Frequency of lymph node invasion was assessed at different sites. When the frequency reached more than 50%, the
mean diameter of the lymph node metastases is indicated. aMean diameter expressed in mm+s.d.; bThe mediastinal lymphatic tissue invasion
was semi-quantitatively evaluated on a scale from -, equivalent to the absence of invasion, to 5+, corresponding to the maximum; Clndicates
invasion of the contralateral lymph nodes. P: statistical difference between treated and non-treated tumours, analysed by Student's t test.CZT THERAPY-INDUCED TUMOUR PROGRESSION 471
The S(x)T lineage tumours grew more rapidly than the
NT(x)T tumours (MD 41+1mm vs. 32+1mm on day 32,
P<0.01), were only slightly sensitive to the inhibitory effect
of CZT (MD 37+1 mm vs. 41+1 mm, P<0.05), and became
less sensitive to the CZT enhancing effect on their metastatic
ability (median LM 191, range 23-TMTC, P>0.05) as the
selection proceeded. Whether CZT-treated or not, these
tumours killed their hosts three times more rapidly than the
nontreated 9-4/0 tumour (survival time 32+3 days vs. 86+5
days, P<0.01).
In vitro, the S4T cell line also behaved differently from the
parental cell line. Whereas NT4T and 9-4/0 cells grew in
dense areas and reached confluence in petri dishes, S4T cells
remained isolated from one another, and when the density of
cells caused them to touch, the newly born cells detached
from the dishes (Figure 3B). In soft agar, S4T cells did not
form spheroid aggregates, but migrated into the gel (Figure
3C).
Chromosome analysis
9-4/0 rhabdomyosarcoma is very heterogeneous in terms of
chromosome content. In vitro cultured 9-4/0 cells presented a
wide range of chromosome number/cell, from 30 to 130, so
that no mode could he identified. 1 2 3 4 5 6 7 8 9
11%. UW,
In vivo passages induced a selection that resulted in the Weeks after injection emergence of a modal number of chromosome/cell in the
Kinetics of tumour growth under CZT treatment. RMS NT(x)T lineage (65 + 15 chromosomes/cell for the NT4T
4T and S4T cells were s.c. grafted into groups of 20 line). The CZT pressure increased this selection to an almost
rats, and these were randomly separated into two clonal level in the S4T cell line (70+5 chromosomes/cell).
one group receiving i.p. 10mgkg1 CZT weekly and Even SiT cells had already reached a chromosome content
untreated, until death. As a general rule, tumour- . .
tfe ri-r;v,- th- f;rqt (7T initinn whtn tht tiimniir range (67+17) as limited as the NT4T cells (Figure 4).
NK lysis assay
9-4/0 tumour cells showed a weak sensitivity to NK
cytotoxicity (24.5% of lysis at the effector: target ratio of
100:1). There was no significant change in sensitivity
throughout NT(x)T lineage evolution until NT4T shifted
towards resistance (13.0% lysis at 100:1).
SIT cells were much more NK sensitive than the NT(x)T
lineage and 9-4/0 tumour cells (34.7% lysis at 100:1). S2T,
S3T and S4T cell sensitivities were similar to those of the
parental cells (respectively, 28.0, 22.3 and 25.4% lysis at
100:1) (Figure 5).
Discussion
The alkylating agent CZT, a widely used antitumoral drug,
has a paradoxical effect on the rat RMS 9-4/0 tumour
development. Thus, whilst it slows the primary tumour
growth rate, it also enhances the metastatic invasion of the
lungs (Pauwels et al., 1985). We established that this effect
was due to a direct effect of CZT on the tumour cells, rather
than on the host, as treatment of the rats prior to the
injection of RMS 9-4/0 did not give the same results
(Poupon et al., 1984). We suspected a CZT-resistant sub-
population of the tumour to be highly metastatic, associating
genetic instability and metastatic ability (Cifone & Fidler,
1981) and the postulated relationship between genetic
instability and progression to a more drug-resistant
phenotype by means of the generation and selection of
variants (Goldie & Coldman, 1984; Stephens et al., 1986).
However, when injected into new recipient rats, the in vivo
treated tumour cells were found not to have acquired a
higher metastatic efficiency. In fact, after the drug selection
procedure, the tumour attained a new equilibrium in terms
of drug resistance and metastatic ability amongst other
characteristics. CZT treatment was not sufficient to produce
a fully resistant tumour at the first passage. The purpose of
the experiments described in the present study was to select a
resistant cell population, by means of successive passages
and in vivo CZT treatments of RMS 9-4/0 cells, the control
UUaLlS, 1LaS lI_VWXV L11C; lllbL 1 llLlUll WIlUlI LI1S LUlllVUU
reached a diameter of 10mm. However, NT4T tumour-bearing
rats, as a control for S4T-bearing rats, received CZT as of the
first week, when the s.c. tumour was smaller. The curves
represent the local tumour growth rates of: 0 0 RMS 9-4/0,
F1 C] NT4T, A/-A S4T; open symbols without treatment,
solid symbols with CZT treatment. The first three means
corresponding to the RMS 9-4/0 tumours were calculated with
the pool of rats before their separation into two groups. Stars
indicate the mean time of death.
57, range 12-93, P<0.01) and in the LN. Concomitantly, a
higher tumour growth rate (NT4T MD=43+1mm on day
44 vs. 9-4/0 MD= 15+2mm, P<0.01) and a lower sensitivity
to the inhibitory effect of CZT on tumour growth
(MD=28+3mm vs. 32+1mm on day 32, P<0.05) were
noted. On the contrary, the NT(x)T lineage remained
sensitive to the CZT enhancing effect on the lung metastatic
abilities (median LM 188, range 44- too many to count:
TMTC, P<0.01). Both the primary tumour and the
metastases were identified as well differentiated rhabdomyo-
sarcomas upon histological examination (Figure 3A).
S(x)T lineage The S(x)T tumours rapidly became more
aggressive and invasive. As early as the second in vivo
passage (S2T), the tumour invaded all the inguinal, axillary,
lumbaraortic and mediastinal LN and frequently invaded the
mesenteric LN. It metastasized to the liver in 20% of the
rats, in a diffuse manner, whereas LM were always well
delimited nodules. The number of LM in non-treated S(x)T
tumour-bearing rats grew rapidly to reach the number of
LM in CZT treated 9-4/0 tumour-bearing rats by the fourth
in vivo passage (S4T: median LM 200, range 146-TMTC).
These changes in the metastatic behaviour of the 9-4/0
rhabdomyosarcoma were concomitant with a modification in
the histological aspect of the tumour. Microscopic
examination of S3T tumoral tissue revealed fibroblastic or
histiocytic-like cells with irregular nuclei. These cells were
arranged in a storiform or occasionally fascicular manner.
We also observed polynucleated giant cells, foam cells, and
abundant collagen. Mitogenic activity was elevated (Figure
3A). All these features suggested that S3T tumour had
become a pleiomorphic histiocytoma.
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Figure 3 Morphological characteristics ofthe CZT-treated S4T cell lines compared to those of the RMS 9-4/0 and NT4T cell lines.
Part A: Photomicrographs (x 160) of the histological features of local tumour growth in syngeneic rats. I: RMS 9-4/0 tumour
tissue is seen to be a well differentiated rhabdomyosarcoma, II: NT4T tumour tissue is recognized as a rhabdomyosarcoma, with
numerous mitoses. III: S4T tumour tissue, designated as fibrous histiocytic sarcoma, is characterized by a pleiomorphological,
poorly differentiated aspect, and the absence of giant fusiform cell types. Part B: Photomicrograph (x 250) of cell monolayers
(72h after seeding the same number of cells). I: RMS 9-4/0 (doubling time: 17.5h) characterized by fusiform cells capable of
reaching confluence, and the presence of multinucleated fused cells (myotubes). II: NT4T has an aspect similar to that of RMS 9-
4/0 cells (doubling time: 16h). III: S4T (doubling time: 16h) shows mostly undifferentiated isolated cells, with numerous detached
cells. Part C: Photomicrograph (x 125) of cell colonies in soft agar. RMS 9-4/0 (I) and NT4T (II) present dense spherical colonies,
whereas S4T (III) cells migrate through the agar.
RMS 9-4/0
Chromosome number 40
20 - S1T
10 -t
25 50 75 1 oo
30- S4T
20 -
10 -
____
.~I
25 50 75 1oo 25 50 75 1oo
Figure 4 Chromosome analysis of the different cell lineages. The
chromosome number was counted in 100 metaphases/cell line.
An interval of 5 chromosomes was alloted to the representation
scale in order to minimize count errors.
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Figure 5 Sensitivity of the different cell lines to NK lysis at
spleen to tumours cell ratios of25, 50, 100 and 200:1. Heavy lines
represent the cytotoxicity curve corresponding to the RMS 9-4/0
cells, identical in both figures. The left hand portion of the figure
shows the evolution of NT(x)T lineage NK sensitivity. The
changes of S(x)T lineage NK sensitivity are shown on the right:
O O 1st passage, A/ A 2nd passage, LI 0 3rd
passage, * * 4th passage.
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being obtained through successive in vivo grafts without CZT
treatment.
The NT(x)T control lineage demonstrated a marked
progression towards a more aggressive behaviour. We
observed an accelerated growth rate, an increased invasive
ability, and interestingly, an increased resistance to CZT,
despite the fact that the cells had not been previously in
contact with the drug.
The possibility that successive in vivo passages of tumour
cells select the most aggressive subpopulations of the
parental tumour has been suggested by the report that
enhanced metastatic ability occurred after the repeated
passage of either metastases (Talmadge & Fidler, 1982) or
the primary tumour (Vaage, 1980). Among the tumour cells
subcutaneously injected into the animal, those which are the
most able to resist host defenses, to attach to, and invade,
the surrounding tissue, and which proliferate the most
rapidly, would probably overpopulate the whole tumour.
Metastatic subpopulations obviously possess all these
properties, and could be selected in this way. Nowell (1976)
proposed a model of tumour progression towards
malignancy, dependent upon the rate of mutation of the
tumour cells. Lengthening the tumour's life span by
transplanting it over years may enhance this progression,
allowing late variants to be generated. In a recent article, Bal
de Kier Joffe et al. (1986) proposed that a short in vitro
passage between two in vivo transplantations could also
induce the selection of more aggressive tumour cells, as the
result of an increased synthesis of specific binding proteins.
This kind of selection conforms with the evolution of the
NT(x)T lineage. Karyotypic analysis revealed a narrowing of
the chromosome content range, suggesting a real selection of
cells the best able to survive. Results of the NK lysis
sensitivity assay showed that NT(x)T lineage tumours
progressively increased in resistance to NK lymphocytes, but
only NT4T cells differed significantly from the parental
RMS 9-4/0 cells in all our experiments.
In addition to the selection imposed upon the NT(x)T
lineage, the S(x)T lineage tumours underwent CZT-induced
treatment toxicity and mutagenicity. When successively
grafted tumours were kept under constant CZT treatment,
progression to severe aggressivity occured. Although the
tumour growth rate and the primary tumour sensitivity to
CZT were only slightly changed compared to the control
NT(x)T tumour, the spontaneous invasive ability
dramatically increased to reach the invasiveness of the RMS
9-4/0 tumour in CZT-treated rats. Furthermore, the liver, a
new target organ, was colonized, no metastases being found
in this organ in rats bearing tumours induced by the grafting
of either RMS 9-4/0, NT(x)T lineage, or S(x)T lineage
before the 2nd in vivo passage. This change in metastatic
behaviour occurred concomitantly with a shift in the histo-
logical aspect of the tumoral tissue. Fibrous histiocytic
neoplasms with predominantly histiocytic differentiation
have been described to be highly malignant, and to invade
preferentially lung, liver, lymph nodes and mesentery
(Greaves & Faccini, 1981). Although the histogenesis of
fibrohistiocytic tumours is not yet completely defined, it
seems highly unlikely that they are closely related to
rhabdomyosarcomas. We ascribe this striking change of
S(x)T lineage behaviour to a treatment-induced genetic
alteration. This is supported by the fact that alkylating
agents demonstrate mutagenic properties (Bradley et al.,
1980; Franza et al., 1980).
The modified histology of S(x)T lineage tumours
correlates with several of our experimental findings. Previous
studies (Hart, 1982; Nicolson & Custead, 1982; Tarin &
Price, 1981; Tarin et al., 1984) tended to show that it is
impossible to adapt metastatic cells to new target organs, but
the capacity to disseminate to the liver, as acquired by late
S(x)T passages, is inherent to fibrohistiocytic tumours.
Sensitivity to NK cell lysis may be related to the tumour cell
stage of differentiation (Werkmeister et al., 1982). Thus,
whereas we might have expected an increased resistance of
S(x)T lineage tumours to NK lysis, S2T was significantly
more sensitive than RMS 9-4/0 parental cells. Metastatic
ability may well increase together with susceptibility to NK
lysis, if the number of circulating tumour cells becomes
sufficiently high to overcome NK function. Although not
significant, a weak selection of more resistant cells appeared
to occur over subsequent passages. The narrowing of the
chromosome content range of the S(x)T lineage compared
with the NT(x)T lineage cannot be ascribed to selection by
CZT, as we noted that the NT4T tumour was actually as
resistant to CZT toxicity as S4T. It is more likely that a new
fibrohistiocytic population emerged and became predominant
with in vivo passages.
However, the histologic divergence of the S(x)T lineage
could explain neither the enhancement of metastatic capacity
of RMS 9-4/0 tumours in rats treated with CZT, nor why
this effect was not observed when the S4T tumour was
treated by CZT. Previous results (Pauwels et al., 1985,1986)
suggest that alkylating agents might act as inducers of
proliferation of RMS 9-4/0 and 9-4/0-derived tumour cells.
Quiescent disseminated cells may, therefore, have given rise
to metastases when treated. This characteristic induced by
CZT could have become permanent in S4T cells, thus
masking any enhancement of their metastatic behaviour after
treatment.
Metastases are known to frequently resist therapy, but
only a few reports have described an enhancement of tumour
dissemination subsequent to chemotherapy. Various authors
(Van Putten et al., 1975; Steel & Adams, 1977) showed that
cyclophosphamide pre-treatment could increase, by more
than 1000-lold, the number of lung colonics in a mouse
mammary tumour model. This effect was related to drug
cytotoxicity against host tissue. Lazo et al. (1978) found an
enhancement of lung colonies after in vitro treatment of B16
melanoma cells with ICRF-159, an agent known to reduce in
vivo metastatic formation, and concluded that the drug had a
specific effect on the tumour cells. More recently, McMillan
et al. (1986) reported a greater than 10-fold increase in the
lung colonizing abilities of B16 melanoma sublines treated in
vitro with hydroxyurea (HU) and allowed to recover 24h
before injection. They related this effect to the mutagenic
properties of HU which lead to gene amplification. In all of
these experiments, i.v. injection of tumour cells was chosen
as the metastatic model. This procedure reproduces the final
steps of the metastatic process, that seem to be implicated in
the therapy-induced enhancement of tumour dissemination.
Our model of spontaneous metastasis includes the necessity
for the tumour cells to escape from the primary tumour and
enter the vascular system. This could for example involve the
motility and the degradative abilities of the tumour cells, as
evidenced by our studies of S4T cells in vitro (unpublished
results). Finally, our work highlights the danger of in vivo
treatment of well-established tumours with potentially
mutagenic chemotherapeutic agents, a problem to which
Kerbel and Davies have drawn cancerologists' attention
since 1982.
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